These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 28470147)

  • 1. Assessment of urinary pharmacokinetics and pharmacodynamics of orbifloxacin in healthy dogs with ex vivo modelling.
    Shimizu T; Harada K; Manabe S; Tsukamoto T; Ito N; Hikasa Y
    J Med Microbiol; 2017 May; 66(5):616-621. PubMed ID: 28470147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose.
    Well M; Naber KG; Kinzig-Schippers M; Sörgel F
    Int J Antimicrob Agents; 1998 Apr; 10(1):31-8. PubMed ID: 9624541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose.
    Boy D; Well M; Kinzig-Schippers M; Sörgel F; Ankel-Fuchs D; Naber KG
    Int J Antimicrob Agents; 2004 Mar; 23 Suppl 1():S6-16. PubMed ID: 15037323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of minimum biofilm eradication concentrations of orbifloxacin for canine bacterial uropathogens over different treatment periods.
    Shimizu T; Harada K
    Microbiol Immunol; 2017 Jan; 61(1):17-22. PubMed ID: 28042660
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Wenzler E; Meyer KM; Bleasdale SC; Sikka M; Mendes RE; Bunnell KL; Finnemeyer M; Rosenkranz SL; Danziger LH; Rodvold KA
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary Concentrations and Antibacterial Activity of BAL30072, a Novel Siderophore Monosulfactam, against Uropathogens after Intravenous Administration in Healthy Subjects.
    Straubinger M; Blenk H; Naber KG; Wagenlehner FM
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3309-15. PubMed ID: 26976871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of metabolites isolated from the urine samples of cats and dogs administered orbifloxacin.
    Matsumoto S; Takahashi M; Kitadai N; Katae H
    J Vet Med Sci; 1998 Nov; 60(11):1259-61. PubMed ID: 9853310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary concentrations and antimicrobial activity of tobramycin in healthy volunteers receiving a single oral dose of a novel formulation for improved absorption.
    Loose M; Naber KG; Shields P; Reinhart H; Wagenlehner FME
    Int J Antimicrob Agents; 2018 Mar; 51(3):422-426. PubMed ID: 29158143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of pharmacokinetic and pharmacodynamic indices of orbifloxacin in beagle dogs after a single intravenous and intramuscular administration.
    Gebru E; Lee JS; Chang ZQ; Hwang MH; Cheng H; Park SC
    Antimicrob Agents Chemother; 2009 Jul; 53(7):3024-9. PubMed ID: 19398644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Japanese nationwide surveillance in 2011 of antibacterial susceptibility patterns of clinical isolates from complicated urinary tract infection cases.
    Ishikawa K; Hamasuna R; Uehara S; Yasuda M; Yamamoto S; Hayami H; Takahashi S; Matsumoto T; Minamitani S; Kadota J; Iwata S; Kaku M; Watanabe A; Sunakawa K; Sato J; Hanaki H; Tsukamoto T; Kiyota H; Egawa S; Deguchi T; Matsumoto M; Tanaka K; Arakawa S; Fujisawa M; Kumon H; Kobayashi K; Matsubara A; Wakeda H; Amemoto Y; Onodera S; Goto H; Komeda H; Yamashita M; Takenaka T; Fujimoto Y; Tsugawa M; Takahashi Y; Maeda H; Onishi H; Ishitoya S; Nishimura K; Mitsumori K; Ito T; Togo Y; Nakamura I; Ito N; Kanamaru S; Hirose T; Muranaka T; Yamada D; Ishihara S; Oka H; Inatomi H; Matsui T; Kobuke M; Kunishima Y; Kimura T; Ichikawa T; Kagara I; Matsukawa M; Takahashi K; Mita K; Kato M; Okumura K; Kawanishi H; Hashimura T; Aoyama T; Shigeta M; Koda S; Taguchi K; Matsuda Y
    J Infect Chemother; 2015 Sep; 21(9):623-33. PubMed ID: 26166322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers.
    Naber KG; Theuretzbacher U; Kinzig M; Savov O; Sörgel F
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1659-65. PubMed ID: 9661000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant prevention concentration of orbifloxacin: comparison between Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus pseudintermedius of canine origin.
    Shimizu T; Harada K; Kataoka Y
    Acta Vet Scand; 2013 May; 55(1):37. PubMed ID: 23634902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary concentrations and antibacterial activities of nitroxoline at 250 milligrams versus trimethoprim at 200 milligrams against uropathogens in healthy volunteers.
    Wagenlehner FM; Münch F; Pilatz A; Bärmann B; Weidner W; Wagenlehner CM; Straubinger M; Blenk H; Pfister W; Kresken M; Naber KG
    Antimicrob Agents Chemother; 2014; 58(2):713-21. PubMed ID: 24217699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-antibiotic effect of orbifloxacin against Escherichia coli and Pseudomonas aeruginosa isolates from dogs.
    Harada K; Shimizu T; Kataoka Y; Takahashi T
    Acta Vet Scand; 2012 Mar; 54(1):16. PubMed ID: 22433170
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Lepak AJ; Zhao M; VanScoy B; Taylor DS; Ellis-Grosse E; Ambrose PG; Andes DR
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28396549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary bactericidal activity of extended-release ciprofloxacin (1,000 milligrams) versus levofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose.
    Wagenlehner FM; Kinzig-Schippers M; Tischmeyer U; Wagenlehner C; Sörgel F; Naber KG
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3947-9. PubMed ID: 16982785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A UK multicentre study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection.
    Farrell DJ; Morrissey I; De Rubeis D; Robbins M; Felmingham D
    J Infect; 2003 Feb; 46(2):94-100. PubMed ID: 12634070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of TEM and CTX-M genes from ciprofloxacin resistant Proteus mirabilis and Escherichia coli isolated on urinary tract infections (UTIs).
    Rajivgandhi G; Maruthupandy M; Manoharan N
    Microb Pathog; 2018 Aug; 121():123-130. PubMed ID: 29778819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary excretion and bactericidal activity of intravenous ciprofloxacin compared with oral ciprofloxacin.
    Naber KG; Theuretzbacher U; Moneva-Koucheva G; Stass H
    Eur J Clin Microbiol Infect Dis; 1999 Nov; 18(11):783-9. PubMed ID: 10614952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of urinary pharmacokinetic and pharmacodynamic profiles of faropenem against extended-spectrum
    Harada K; Shimizu T; Miyashita N; Hikasa Y
    Access Microbiol; 2019; 1(1):e000004. PubMed ID: 32974491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.